Prevention of Preterm Labor
Each year, more than one million babies die as a result of preterm delivery. This number has been static over the last forty years. Approximately 1 in 8 pregnancies deliver preterm and 25% of all pregnancies are at-risk.


KynderMed possesses both near term clinical development opportunities, combined with additional product evolution plans and proprietary approaches to developing other first-in-class novel therapeutics.

KynderMed’s most advanced patented technology, a medical device called CERULEAN SLEEP, is currently undergoing a second round of human testing for the regulation of melatonin and prevention of contractions.

The technology has been shown to be both safe and effective. It is anticipated that the device will complete design work, usability testing, additional human studies and receive US and EU marketing approvals by the end of 2016.

In addition, KynderMed plans to subsequently launch a number of identified medical and usability enhancements.

KynderMed also plans to develop a proprietary, new pharmaceutical technology focused on improving the safety and comfort of labor induction.


Light as a Drug
Dr. James Olcese’s seminal research defined a synergistic relationship between melatonin and oxytocin, which promotes contractions. He further determined that the acute inhibition of melatonin lowers the incidence of nocturnal

KynderMed’s first initiative is a simple, non-invasive medical device that will safely and effectively enable at-risk women to avoid the onset of premature labor. The device uses a specific blue light spectrum to control the

kyndermed wins cade